News

Company receives its first Ebola-related BARDA task order for its HHS-designated center for innovation in advanced development and manufacturing.

Patient-friendly wearable injector utilized in multiple active drug development programs.

Guenter, Meeker and Witz appointed to lead new Global Business Units.

Consolidation of Cambridge research centers creates a single Pfizer Cambridge campus to help expedite discovery and development efforts and encourage creative collaboration.

Researchers have found that nanomaterials and UV light can “trap” chemicals for easy removal from soil and water.

A collaborative team from The University of Texas Medical Branch at Galveston and the National Institutes of Health have developed an inhalable vaccine that protects primates against Ebola.

Ablynx has announced it has expanded its nearly year-and-a-half-old immuno-oncology collaboration with Merck & Co. to address additional checkpoint modulator targets.

Xoma have announced that their monoclonal antibody gevokizumab it is co-developing with Servier has failed the Phase III EYEGUARD-B trial in patients with Behçet's disease uveitis.

A type of drug used to treat diabetes may reduce the risk of developing Parkinson’s disease, according to new research.

An automated management tool that identifies, distributes and manages patients and their mobile device.